Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Uterine Artery Blood Flow in Recurrent Pregnancy Loss
NCT04718233Phase 2Completed
- Sponsor
- Ain Shams University
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP-001 in recurrent pregnancy loss (RPL) (2 arms), sponsored by Ain Shams University. Primary endpoints: Uterine Artery Pulsatility Index at 3 hours, Uterine Artery Resistance Index at 3 hours and 2 more. Started Sep 2018; status: completed.
02
Drugs
ASP-001
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT04718233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718233.